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In contrast to many animal model studies, immunotherapeutic trials in humans suffering
from cancer invariably result in a broad range of outcomes, from long-lasting remissions to no
discernable effect.
Methods and Findings
In order to study the T cell responses in patients undergoing a melanoma-associated peptide
vaccine trial, we have developed a high-throughput method using arrays of peptide-major
histocompatibility complexes (pMHC) together with antibodies against secreted factors. T cells
were specifically immobilized and activated by binding to particular pMHCs. The antibodies,
spotted together with the pMHC, specifically capture cytokines secreted by the T cells. This
technique allows rapid, simultaneous isolation and multiparametric functional characterization
of antigen-specific T cells present in clinical samples. Analysis of CD8þ lymphocytes from ten
melanoma patients after peptide vaccination revealed a diverse set of patient- and antigen-
specific profiles of cytokine secretion, indicating surprising differences in their responsiveness.
Four out of four patients who showed moderate or greater secretion of both interferon-c (IFNc)
and tumor necrosis factor-a (TNFa) in response to a gp100 antigen remained free of melanoma
recurrence, whereas only two of six patients who showed discordant secretion of IFNc and
TNFa did so.
Conclusion
Such multiparametric analysis of T cell antigen specificity and function provides a valuable
tool with which to dissect the molecular underpinnings of immune responsiveness and how
this information correlates with clinical outcome.
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Antigen-speciﬁc cellular immune responses are mediated
by abT cell receptor (TCR)-bearing T cells that recognize
speciﬁc peptides bound to major histocompatibility complex
(MHC) molecules on the surfaces of other cells. These T cells
form a major part of the adaptive immune response. CD8þT
cells mediate direct lysis of infected or aberrant cells, whereas
CD4þT helper cells modulate antibody (B cell) responses and
those of other cells. T cells may become activated following
antigen recognition and respond by secreting soluble factors,
which include mediators of target cell lysis, pleiotropic
effector factors, growth factors, and inﬂammatory and
regulatory cytokines (Table 1). This is a highly regulated
and complex process. In many cases, antigen recognition by
primed CD8þ T cells leads to the lysis of cellular targets and
the release of inﬂammatory cytokines. Alternatively, this
response may be partially or completely anergic.
For many years, investigators have sought to direct T cell
responses against tumors by vaccination [1]. These efforts
have been greatly aided by the discovery of many peptide
antigens that are displayed on MHC molecules on the surface
of tumor cells and that have been shown to elicit T cell
responses both in vitro and in vivo [2,3]. This discovery has
given rise to a variety of strategies, including protein and
peptide vaccination [4], adoptive cellular therapy [5], cyto-
kine therapy (i.e., interleukin [IL]-2, granulocyte-macrophage
colony-stimulating factor [GM-CSF], interferon [IFN] a) [6–8],
and immune response modiﬁers such as anti-CTLA4 [9,10].
Despite intense efforts, the success of most of these protocols
has been mixed. Although in many cases, speciﬁc T cell
responses can be generated in patients (or expanded ex vivo
and reintroduced intravenously), they are not usually
effective against the tumor. A large part of the problem
may be that most of these tumor-associated antigens are
normal ‘‘self’’ peptides, and responses may be naturally
suppressed. In this context, it is important to monitor the
precise functional status of T cells that are elicited by a
particular immunization protocol, and to determine what
conditions result in T cells that are the most effective in
bringing about clinically signiﬁcant results. For this purpose,
the ability to track antigen-speciﬁc T cells with peptide-MHC
(pMHC) tetramers [11] has been an important tool in the
identiﬁcation and characterization of lymphocytes capable of
recognizing speciﬁc tumor antigens. This technique, together
with other assays (e.g., intracellular cytokine staining, CD107,
ELISpot, killing assay) have been used to try to address T cell
function [12–15]. However, these assays are labor intensive,
require large quantities of clinical peripheral blood mono-
nuclear cell (PBMC) specimens for a comprehensive analysis,
have poor spatial resolution and/or low sensitivity for
secreted responses, and do not address the growing need to
track multiple T cell speciﬁcities for different functional
events. To overcome these limitations, we previously reported
on an array-based approach to capture and quantitate
antigen-speciﬁc T cells based on their adherence to pMHC
complexes [16]. Here, we report a further development of this
technology, in which we combined the high-throughput
capture and activation of antigen-speciﬁc T cells described
previously with the simultaneous analysis of the secretion of a
wide variety of factors with single-cell resolution. Using this
technique, we assess antigen-speciﬁc T cells from different
vaccine recipients and analyze different functional proﬁles
following antigen recognition in an attempt to explore the
variability of clinical outcomes that is characteristic of tumor
vaccine trials.
Methods
Peptides and Cell Lines
The peptides gp100 209–2M (IMDQVPFSV), MART1 M26
(ELAGIGILTV), tyrosinase 370D (YMDGTMSQV), gp100 209
(ITDQVPFSV), MART1 27–35 (AAGIGILTV), CMV pp65 495–
503 (NLVPMVATV), EBV BMLF1 280–288 (GLCTLVAML),
and inﬂuenza MP 58–66 (GILGFVFTL) were produced at the
Protein and Nucleic Acid Facility at Stanford University
(Stanford, California, United States).
CD8þ T cell clones were derived and maintained as
previously described [17]. Brieﬂy, clones were derived from
melanoma patients or healthy donors expressing the human
leukocyte antigen (HLA)-A2.1 MHC molecule. Clone 132.2
speciﬁcally binds gp100 209 or gp100 209–2M/HLA-A2.1.
Clones 461.30 and 461.24 speciﬁcally bind MART 27–35 or
M26/HLA-A2.1. Clone CMV94.3 speciﬁcally binds CMV pp65
495–503/HLA-A2.1 and was derived by ﬂuorescence-activated
cell sorter (FACS) separation of individual tetramer-positive
cells from PBMCs from a healthy donor. T cell clones were
cultured in CTL medium (Iscove’s modiﬁed Dulbecco’s
medium, with 10% fetal calf serum, 2% human AB sera,
and standard cell-culture concentrations of penicillin, strep-
tomycin, and L-glutamine) supplemented with 50 U/ml IL-2.
The clones were expanded by stimulation with phytohemag-
glutinin (Invitrogen, Carlsbad, California, United States) at a
Table 1. Factors Secreted by Lymphocytes or Other Cells of the
Immune System
Class Factors References
Mediators of cell lysis Granzyme B 38
Granzyme A 39
Perforin 40
Pleiotropic factors IFNc 41
TNFa 42
TNFb 43
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Human Tumor-Specific T Cell Function1:100 dilution, followed by 14 d of culture in CTL medium
with irradiated feeder cells and 50 U/ml of IL-2. Following
expansion, clones were either cryopreserved or maintained in
culture with CTL medium supplemented with 50 U/ml IL-2 or
2 ng/ml IL-15, and used within 2 wk. Cryopreserved cells were
thawed at least 2 d prior to assays, and were suspended in
CTL medium with 100 U/ml IL-2. At 1 d prior to experiments,
the clones were transferred to fresh CTL medium without
interleukins.
Preparation of pMHC Class I
The pMHC tetramers were developed in the Davis lab and
were prepared as previously described [11]. Alternatively,
tetramers were purchased from Beckman Coulter (Allendale,
New Jersey, United States). The pMHC dimers were pur-
chased from BD Pharmingen (San Diego, California, United
States) and prepared per manufacturer’s protocol. All pMHC
constructs were supplemented with glycerol prior to printing
(2% ﬁnal concentration).
Vaccination Protocol
A randomized phase II trial for patients with resected
stages IIC/III and IV melanoma who were HLA A*0201-
positive and expressed at least one of the following was
conducted: HMB-45 (gp100), tyrosinase, or Melan-A (MART-
1). Informed consent was obtained from all patients. A total
of 60 patients were randomly allocated to receive three
peptides at 1 mg each (gp100 209–2M, tyrosinase 370D, and
MART-1 M26) emulsiﬁed with the adjuvant Montanide ISA 51
in a 1:1 ratio by volume with: (A) IL-12 at 30 ng per kilogram
body weight, (B) IL-12 at 100 ng per kilogram, and (C) IL-12 at
30 ng per kilogram with GM-CSF at 83 lg per peptide
emulsiﬁed. All patients had a CT scan of the chest/abdomen/
pelvis and brain MRI required to show no evidence of disease
within 28 d of initiation of vaccine treatment. Injections were
given at weeks 0, 2, 4, 6, 10, 14, 18, and 26, then week 50 for a
total of nine injections over 1 y. Leukopheresis was
performed just prior to the ﬁrst injection and within 2 wk
after injection number 8 (week 28) for immune response
assays. Smaller blood samples were obtained at 3, 9, and 12
mo. Clinical specimens were frozen and stored prior to use, as
previously described [18,19]. Tetramer ﬂow cytometry on
pretreatment blood samples showed no detectable melanoma
antigen-speciﬁc T cells.
Antibodies
Antibodies against human CD8 (HIT8a), HLA-A2 (BB7.2),
IFNc (NIB42, 4S.B3), TNFa (MAb1, MAb11), granzyme B (2CF/
F5, GB11), GM-CSF (BVD2-23B6, BVD2-21C11), IL-2
(5344.111, B33–2), IL-4 (8D4–8, MP4-25D2), IL-5 (TRFK5,
JES1-5A10), IL-10 (JES3-9D7, JES3-12G8), and IL-12p70
(20C2, C8.6) were purchased from BD Pharmingen (San
Diego, California, United States); antibodies against IL-1a
(4414.141, pAb BAF200), IL-1b (8516.311. pAb BAF201), IL-3
(4815.211, pAb BAF203), IL-6 (6708, pAb BAF206), IL-7 (7417,
pAb BAF207), IL-13 (32116, pAb BAF213), IL-15 (34593, pAb
BAF247), IL-17 (41809, pAb BAF317), lymphotactin (109001,
pAb BAF695), IP-10/CXCL10 (33036.211, pAb BAF266), TGF-
b1 (9005, 27240), TNFb (5807, pAb BAF211), vascular
endothelial growth factor (VEGF; pAb AF293NA, pAb
BAF293), and VEGF-D (78902, 78923) were purchased from
R&D Systems (Minneapolis, Minnesota, United States), and
granzyme A (CLB-GA29, CLB-GA28) was purchased from
Research Diagnostics Incorporated (Flanders, New Jersey,
United States). Clone names are listed in parentheses, with
biotinylated antibody clone names listed second, where
appropriate. Polyclonal antibodies are noted with a pAb
preﬁx.
Preparation of pMHC Functional Microarrays
Libraries of pMHC/antibody mixtures were prepared as
follows: Each of the pMHC constructs was mixed with a panel
of antibodies against potentially secreted factors (Table 1),
such that each mixture contained a single pMHC construct
(2.5 mg/ml ﬁnal concentration) and a single antibody against a
secreted factor (0.5–1mg/ml ﬁnal concentration). Each of
these pMHC-based mixtures was supplemented with 2%
glycerol. A second library with 0.5 mg/ml of either anti-
human CD8 or anti-human HLA-A2 (instead of pMHC) and
an antibody against a secreted factor was prepared as a
nonactivating control. A volume of 12 ll of each mixture was
loaded into a 384-well plate (MJResearch, Waltham, Massa-
chusetts, United States) and arrayed in triplicate onto three-
dimensional substrates composed of microscope slides coated
with a polyacrylamide gel (Perkin Elmer, Boston, Massachu-
setts, United States), preprocessed according to the manu-
facturer’s instructions. Samples were dispensed using a non-
contact piezoelectric arrayer (Perkin Elmer), such that each
spot contained ten drops of approximately 0.45 nl each.
Printed proteins were immobilized within the gel substrate by
incubating the slides for 48 h at 4 8C in a humid chamber.
Following the immobilization, the arrays were placed in a dry
slide box, sealed with tape, and stored at 4 8C until use. Arrays
were tested for speciﬁc capture of secreted factors using
deﬁned concentrations of recombinant human factors
(Quantikines, R&D Systems) incubated on an unused array
for 30 min at room temperature, followed by 12 h at 4 8C.
Arrays were then washed, developed, and imaged, as
described below.
Flow Cytometry Analysis
Patient PBMCs were analyzed for G209-2M-tetramer
reactive cells by ﬂow cytometry as described previously [13].
Brieﬂy, cells were reacted with G209-2M-tetramer-PE (Beck-
man Coulter Immunomics Operations, San Diego, CA,
United States) at 1:200 dilution for 20 min at room temper-
ature, followed by anti-CD19 FITC (Caltag Laboratories,
Burlingame, California, United States) and anti-CD8 PerCP-
Cy5.5 (BD Biosciences, San Jose, California, United States)
antibodies at ﬁnal staining dilution of 1:40 and 1:20,
respectively, for an additional 20 min. Cells were then washed
and analyzed using a FACSCalibur ﬂow cytometer (Beckton
Dickinson, San Jose, California, United States). Approxi-
mately 10
5 events were acquired from each sample and
analyzed using FlowJo software (TreeStar, San Carlos,
California, United States). Plotted CD19 , CD8þ, tetramerþ
lymphocytes were calculated as percent of total CD8þ
lymphocytes for each sample.
Binding and Secretion Assays
Binding and secretion assays were performed with either
patient CD8þ T cells or cultured human CD8þ T cell clones.
CD8þT cells were isolated from 5310
7 PBMCs from patients
on the above-described vaccine protocol, using a CD8 
isolation column (Miltenyi Biotec). The CD8þ T cells were
then resuspended in 200 ll of incubation medium (RPMI
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centrations of penicillin and streptomycin). Alternatively, 13
10
6 CD8þT cell clones, as described above, were resuspended
in 200 ll of incubation medium. For pMHC binding analysis,
the single cell suspension was incubated on the pMHC array
for 10–30 min at 20 8C. At the end of the incubation period,
the array was washed in calcium- and magnesium-free PBS
(CMF) to remove unbound cells and imaged as detailed below.
To analyze cellular secretion, the cells were incubated on the
array in 400 ll of incubation medium at 37 8C for 2 h (CD8þT
cell lines) or for 24 h (patient samples). To determine the
secretion of factors, the arrays were washed in CMF and
incubated in 200 ll of pooled biotinylated antibodies in
staining medium (10% FCS in CMF) for 20 min at 20 8C. The
biotinylated antibodies were each matched to a single,
printed antibody speciﬁc against different epitopes of the
same secreted factor. The ﬁnal concentration of each
biotinylated antibody was based upon concentrations recom-
mended for ELISA or ELISpot, and titrated as necessary.
After incubation with biotinylated antibodies, the array was
washed twice in CMF and stained with 3.3 lg/ml streptavidin-
phycoerythrin (BD Pharmingen) in 200 ll of staining medium
for 20 min at 20 8C in the dark. The array was dip-washed
twice again in CMF and then imaged as detailed below.
Image Acquisition and Analysis
Imaging was performed using a Zeiss Axiovert-200 micro-
scope (Oberkochen, Germany) ﬁtted with a high-speed piezo
electric z-motor stage (Applied Scientiﬁc Instrumentation,
Eugene, Oregon, United States), a 103Zeiss Fluor objective, a
CCD camera (Roper Scientiﬁc, Trenton, New Jersey, United
States), and dual excitation and emission ﬁlter wheels (Sutter
Instruments, Novato, California, United States). DIC and Cy3
images were collected from each spot on the array. Image
acquisition was controlled by Metamorph (Universal Imaging,
Downingtown, Pennsylvania, United States). Image analysis,
feature extraction, and data analysis were performed using
Metamorph, ImageXpress (Molecular Devices, Union City,
California, United States), and Matlab Software (The Math-
Works, Natick, Massachusetts, United States).
Analysis of Patient Data
Scoring of patient samples was performed in a blinded
fashion. Coded samples were scored without prior informa-
tion regarding patient age, sex, therapy, clinical, or immuno-
logical outcome. Scoring was based on a ﬁve-point scale (i.e.,
0–4), with 0 representing background signal. A cell count
score for IFNc and TNFa secretion was based upon the
number of responding cells per spot: 0, no response; 1, 1–5; 2,
6–10; 3, 11–20; and 4, more than 21 responding cells. A
second score, for intensity, was based on average integrated
pixel ﬂuorescence over all replicate spots (after subtraction
of the average integrated pixel ﬂuorescence of control spots
containing only pMHC). Each of the averaged intensities was
normalized by a value greater than the highest intensity for
that particular secreted factor, across all patients and
expressed as a percentage of that value. The intensity score
was assigned as follows: 0, 0%–5%; 1, 6%–25%; 2, 26%–50%;
3, 51%–76%; and 4, 77%–100%. A combined score for IFNc
and TNFa was obtained by adjusting the cell count score up
or down by 1 if the intensity score was higher or lower than
the cell count score. Scores for secreted factors lacking clear
and consistent focal secretion across all patients (including
granzyme B, IL-2, TGFb, IL-1b, IL-6, GM-CSF, IL-1a, IL-3, IL-
4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, IL-17, lympho-
tactin, IP-10, TNFb, VEGF, VEGF-D, and granzyme A)
received only intensity scores according to the following
scale: 0, 0%–5%; 1, 6%–19%; 2, 20%–50%; 3, 51%–80%; and
4, 81%–100%. Six clinical specimens were initially tested
using the pMHC functional array. Five additional specimens
were tested to assess consistency of ﬁndings and expand the
number of analyzed specimens.
Results
Specific Capture of Human Antigen-Specific T Cells Using
a Readily Scalable pMHC Array
In our earlier work, we used pMHC tetramers spotted onto
arrays to capture and quantitate speciﬁc T cells [16]. This has
the disadvantage that the synthesis of pMHC tetramers is
time consuming and not easily scalable to survey large
numbers of different pMHC complexes. To address this
problem, we used dimeric HLA-A2-immunoglobulin (Ig)-
containing molecules (DimerX, BD Biosciences) [20] that lack
peptide and are readily loaded with speciﬁc peptide antigens.
In this way, dozens and potentially thousands of pMHCs can
be made simultaneously. We tested the speciﬁcity of capture
of these molecules using melanoma-speciﬁc antigens and two
well-characterized human CD8þ Tc e l ll i n e so np M H C
microarrays printed on polyacrylamide-coated slides. The
CD8þ T cell clones 132.2 and 461.30 were originally isolated
from two patients vaccinated with gp100 209–2M peptide and
MART1 M26 peptide [17] and expanded in vitro. Using ﬂow
cytometry, 132.2 stains exclusively with the gp100 209–2M/
HLA-A2.1 tetramer while 461.30 stains with MART1 M26/
HLA-A2.1, but not the gp100 209–2M/HLA-A2.1 tetramer. A
microarray using pMHC constructs (gp100 209–2M/HLA-A2.1
tetramer, gp100 209–2M/HLA-A2.1 dimer-Ig, gp100 154/HLA-
A2.1 dimer-Ig, MART1 M26/HLA-A2.1 tetramer, MART1
M26/HLA-A2.1 dimer-Ig and MART1 27/HLA-A2.1 dimer-Ig
and monoclonal antibodies (anti-CD8a, and anti-HLA-A2)
was constructed. For the assay, 132.2 (gp100-speciﬁc) and
461.30 (MART1-speciﬁc) cells were overlaid onto separate
arrays. While both cells bound to the monoclonal antibody
spots, 132.2 cells bound exclusively to the gp100 pMHC spots,
while 461.30 cells bound only to the MART1 pMHC spots.
Binding to speciﬁc tetramer and dimer spots was equivalent
(Figure 1).
pMHC Arrays Are Sensitive to Low-Frequency T Cell
Populations
We compared the sensitivity of array-based detection to
pMHC tetramer staining and ﬂow cytometry for gp100 209–
2M-speciﬁc CD8þ T lymphocytes from human clinical
samples. PBMC samples collected from a patient pre- and
post-gp100 peptide vaccination were used in this comparison.
FACS analysis using tetramer staining indicated that the pre-
vaccine sample was negative for gp100 209–2M, while the
postvaccine sample contained 0.19% positive CD8þ T cells.
To test the limits of detection in both methods, we diluted
postvaccine CD8þ T cells in the gp100 209–2M negative
prevaccine sample. CD8þ T cells were isolated from both
samples using a depletion column and mixed at post-
vaccine:pre-vaccine ratios of 1:0, 1:2, 1:9, 1:29, and 0:1. Each
mixture was analyzed separately, using a pMHC microarray
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were counted and averaged over ﬁve identical gp100 209–2M/
HLA-A2.1 spots. Both methods were able to detect antigen-
speciﬁc T cells at fractional abundances as low as one cell in
10,000, or 0.01% of the CD8þ population (Figure 2). Cellular
microarray binding variability was minimized by using the
average number of cells bound over the ﬁve replicate spots
printed on the same array. Results of the tetramer/FACS
varied by the selection gate for forward scatter/side scatter,
CD19þ dump and CD8þ/tetramerþ staining. However, both
cellular microarray and tetramer/FACS produced antigen-
speciﬁc T cell frequencies that correlated well with serial
dilution.
Functional Profiling of Secreted T Cell Factors following
Antigen Recognition
To study the functional responses of T cells after antigen
recognition, we combined cell capture molecules (capture
probes) with molecules that bind secreted factors (detector
probes). Mixtures of a capture probe and detector probe were
printed in triplicate on individual spots on the functional
microarray. Seven different pMHC molecules (gp100 209–2M/
HLA-A2.1, MART1 M26/HLA-A2.1, CMV pp65 495/HLA-A2.1,
gp100 209/HLA-A2.1, inﬂuenza MP 58/HLA-A2.1, EBV
BMLF1 280, and tyrosinase 370D) and four different
monoclonal antibodies (anti-HLA-A2, anti-CD8, anti-CD3/
anti-CD28) were used as capture probes. These were
Figure 1. Peptide-MHC Cellular Microarrays
(A) A functional pMHC microarray diagram illustrating the array format. An array of spots containing different capture probes (pMHC molecules)
cospotted with detector probes, which are antibodies against potentially secreted factors. Antigen-specific T cells are captured by recognition of
printed pMHC, and may become activated. Subsequent secretion of specific factors is captured by the printed detector probes. The presence of those
factors is detected by labeled secondary antibodies (developer probes).
(B) Specificity of pMHC T cell capture is peptide-specific. Human CD8þlymphocyte clones 132.2 and 461.30 were incubated on duplicate microarrays,
which included gp100-2M/HLA-A2.1 and MART-1 M26/HLA-A2.1 tetramer and dimer spots. 2M-specific 132.2 cells were exclusively captured by gp100
spots, and M26-specific 461.30 binding was restricted to MART-1 spots. Binding efficiency to pMHC tetramer or dimer of a given specificity was similar.
DOI: 10.1371/journal.pmed.0020265.g001
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monoclonal antibodies speciﬁc for secreted factors (IL-1a, IL-
1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15,
IL-17, IFNc, TNFa, TNFb, GM-CSF, granzyme B, granzyme A,
TGFb, VEGF, VEGF-D, lymphotactin, and IP10). pMHC
functional microarrays capture antigen-speciﬁc T cells,
provide an activating signal, and capture speciﬁc secreted
factor as they are released by a given T cell. The secretion
proﬁle is visualized using a sandwich assay. A mixture of
matched biotinylated monoclonal antibodies (developer
probes) are applied to the array, followed by streptavidin-
phycoerythrin. The identity of each secreted cytokine is
determined from its location on the array. The speciﬁc
capture and detection of soluble factors was conﬁrmed by
directly incubating matched, quantiﬁed soluble factors on the
array.
Four CD8 T cell lines (132.2, 461.24, 461.30, and CMV94.3)
were tested for their functional proﬁles following binding to
their respective cognate antigen spot, or binding to a
nonactivating spot (e.g. anti-CD8, anti-HLA-A2). Individually
immobilized T cells could be visualized by light microscopy,
and correlated with secreted factor captured from speciﬁc
cells (Figure 3A). All antigen-speciﬁc T cell lines exhibited
similar secretion proﬁles following antigen recognition,
characterized by strong IFNc, TNFa, granzyme A (unpub-
lished data), and granzyme B secretion, and weaker GM-CSF
and IL-2 secretion (Figure 3B). Baseline secretion of
granzyme B and GM-CSF were detectable from cells bound
to anti-CD8 and anti-HLA-A2 monoclonal antibody spots,
but were much weaker than antigen-stimulated secretion.
Detection of Heterogeneous Functional Profiles of Tumor-
Associated Antigen-Specific T Cells Using a Functional
pMHC Array
To gain insight into differences in patient responses to
tumor vaccine therapy, we investigated the functional proﬁles
of patient T cells on arrays of pMHC immobilized with
different monoclonal antibodies directed against speciﬁc
secreted factors. Eleven samples were taken from patients
with resected stage IIC to IV malignant melanoma enrolled in
a clinical trial involving gp100 209–2M, MART1 M26, and
tyrosinase 370D peptide injection. These samples were taken
by leukopheresis after eight injections of peptide and IL-12
adjuvant, 6 mo after the ﬁrst injection (one sample was taken
12 mo after the ﬁrst injection). CD8þ T cells were isolated
from 5 3 10
7 PBMCs using a negative isolation column and
incubated on a functional pMHC array at 37 8C and 5% CO2
for 24 h. Secretion proﬁles were detected as described above.
Speciﬁc T cell immobilization was visible within 10 min, as
described previously [16]. Cytokine secretion was detectable
in each clinical sample as a phycoerythrin ﬂuorescent signal
on spots where speciﬁc cytokine capture antibodies had been
printed. Secretion from individual immobilized cells resulted
in the highly localized capture of cytokine. Different
cytokines had different typical appearances on the array
(Figure 4). IFNc capture resembled a ‘‘starburst’’ pattern
emanating from speciﬁcally bound cells, whereas TNFa
capture resembled a thin ring around the cell. Some
cytokines produced a diffuse signal, which may have resulted
either from saturation of capture reagent on a given spot, or
secretion from unbound bystander cells rather than specif-
ically captured and activated cells responding to a printed
antigen. We characterized the secretion proﬁles for each
patient sample (Figure 5). Quantitative data extracted from
each image included average spot intensity, reﬂecting the
total amount of a given cytokine captured on a spot; spot
intensity standard deviation, which reﬂects granularity of the
developed signal; and the number of responding cells. The
gp100-speciﬁc CD8þ T cells from four samples from three
patients, 10721, 10739, 10735, and 10794 (10735 and 10794
were isolated from the same patient, at 6 and 12 mo,
respectively) gave strong IFNc and TNFa secretion signals. All
three patients remain disease free 25, 21, and 22 mo,
respectively, after initiating vaccine therapy. The gp100-
speciﬁc CD8þT cells from patient 10722 also responded with
similar IFNc and TNFa secretion. At this writing, this patient
remains without evidence of disease progression after 25 mo.
In contrast, four of six patients in whom gp100-speciﬁc CD8þ
T cells mounted a strong IFNc response, or a strong TNFa
response, but not both (Figure 6), experienced a relapse of
disease (patient samples 10710, 10737, 10713, and 10757 at 8,
Figure 2. Sensitivity of pMHC-Specific T-Cell Detection
The sensitivity of array-based T cell detection was compared to FACS-based detection. Patient PBMCs post-gp100 peptide vaccination were serially
diluted in corresponding prevaccination sample. The dilution series was analyzed by both methods. Blue-labeled data correspond to the average
number of bound cells per spot on the array (left graph) or the frequency of cells measured by FACS (right graph). The limit of detection in both
methods was similar. Average number of bound cells per spot was obtained from five replicate spots on the same array. Error bars denote standard
error of the mean across replicates. Red curves denote predicted results based on the values measured for the undiluted sample.
DOI: 10.1371/journal.pmed.0020265.g002
PLoS Medicine | www.plosmedicine.org October 2005 | Volume 2 | Issue 10 | e265 1023
Human Tumor-Specific T Cell FunctionFigure 3. Profiling T Cell Function
Clonally derived MART-1/A2 specific human CD8þT cells were incubated on a functional pMHC microarray on which individual spots contained pMHC
or a control anti-CD8 monoclonal antibody (i.e., capture probes) cospotted with a panel of antibodies against potentially secreted factors (i.e., detector
probes). MART-1-specific cells were immobilized on both MART-1/HLA-A2.1 and anti-CD8 containing spots. Bound cells were further incubated at 37 8C
for 2 h. Secreted factors were captured by the coprinted antibodies at close vicinity to the secreting cells and detected using matched, biotinylated
antibodies. Some of the initially bound cells detached during the staining procedure.
(A) Top and bottom rows display IFNc and TNFa secretions, respectively, each detected at single-cell resolution. The fluorescence images (red) are
overlaid onto the differential interference contrast light microscopy images in the rightmost two columns. Not all immobilized T cells secreted
detectable factors. No T cell binding or fluorescence was detectable on irrelevant pMHC spots (unpublished data).
(B) Secretion profile for 17 different factors. Capture probes are either anti-CD8 antibody (left) or MART1 M26/A2 (right). Cospotted detector probes are
indicated for each spot. Secretion signal is shown in pseudocolor, representing fluorescence intensity. Secreted factor-specific scaling has been applied
to maximize resolution.
DOI: 10.1371/journal.pmed.0020265.g003
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respectively). Three out of four patients in this study that had
strong GM-CSF secretion also remain free of disease at this
writing. IL-1b and IL-6 were both strongly secreted by three
patients, of which only one patient, 10713, has experienced
recurrent disease. Patient response proﬁles to different
antigens did not appear to be global. While some patients
had detectable IFNc responses to a plethora of different
antigens (i.e., 10794), or had no detectable IFNc response to
the tested antigens (i.e., 10742), several patients had detect-
able responses to some antigens, but not others. Patients
10713, 10770, and 10757 failed to generate IFNc secretion in
response to gp100 or MART-1, but were capable of excellent
IFNc secretion in response to viral antigens or a different
melanoma antigen, tyrosinase (Figure 7). Patient 10713 had
no IFNc response to gp100 209–2M/HLA-A2.1, MART1 M26/
HLA-A2.1, or tyrosinase 370D/HLA-A2.1, but a very strong
IFNc response to a common CMV antigen, pp65 495/HLA-
A2.1. These ﬁve samples were also tested for secretion of
IFNc, TNFa, granzyme B, IL-2, IL-1b, and IL-6 in response to
Figure 4. Anatomy of Cytokine Secretion
Secreted cytokine captured as it is released from activated lymphocytes immobilized on a pMHC cellular microarray shows cytokine-specific
configurations. Select representative patient samples are shown for each labeled cytokine to illustrate the patterns of secretion for each individual
cytokine.
DOI: 10.1371/journal.pmed.0020265.g004
Figure 5. Heterogeneity of Melanoma-Associated Antigen-Specific T Cell Responses following Peptide Vaccination
Eleven samples taken from patients enrolled in peptide vaccine trials were analyzed on pMHC functional microarrays. Patients received eight
subcutaneous injections of peptides gp100 209–2M, MART1 M26, and tyrosinase 370D, along with adjuvant in a 6-mo period. Leukopheresis samples
were collected after the eighth injection. Sample 10794 was collected from the same patient as 10735 after month 12. Functional profiles were
generated by incubating patient CD8þ T lymphocytes on pMHC functional microarrays for 24 h at 37 8C and detecting the secreted factors with
biotinylated secondary antibodies and streptavidin-phycoerythrin. Data were analyzed by automated fluorescence microscopy. Responses were scored
on a five-point scale (0 to 4 bars), reflecting number of responders and overall fluorescent signal intensity per spot (Figure S1). Four bars indicate a
strong response, and ‘‘0’’ indicates lack of a response. Each spot was printed in triplicate and analyzed individually. Patient clinical data are listed,
including age and sex ( ‘‘ID’’), stage of disease at enrollment (‘‘Stage’’), and outcome at follow-up (‘‘Outcome’’). Column labeled ‘‘IL12’’ specifies IL-12
adjuvant doses. Patient 10713 also received GM-CSF in addition to IL-12 adjuvant. Other secreted factors not shown include IL-4, IL-5, IL-10, IL-12p70, IL-
1b, IL-3, IL-7, IL-13, IL-15, IL-17, lymphotactin, IP-10/CXCL10, TNFb, VEGF, VEGF-D and granzyme A due to either lack of detectable secretion or limited
analysis performed on only a fraction of the samples. In vitro restimulated cell lines directed against gp100 209 (132.2), MART1 M27 (461.30), or CMV
pp65 495 (CMV94.3) were bound and secreted factors in response to gp100, MART1, and CMV (unpublished data), respectively.
DOI: 10.1371/journal.pmed.0020265.g005
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Human Tumor-Specific T Cell Functiongp100 209/HLA-A2.1 (wild-type peptide sequence). All ﬁve
tested samples showed functional responses to wild-type
gp100 209/HLA-A2.1 that mirrored the measured response to
gp100 209–2M/HLA-A2.1 (unpublished data). Cytokine de-
tector spots were calibrated with recombinant protein, or
cells that secrete those factors. Despite immobilization of
antigen-speciﬁc T cells, spots containing detectors against
other secreted factors are not shown, due to lack of
detectable signal.
Discussion
Cellular immune responses are complex and multifaceted
events involving a multitude of cell types, secreted factors,
microenvironments, cell states, and temporal factors. Under
certain conditions, such as cellular immune responses to viral
infection, the response is capable of eradicating speciﬁc
target cells that express aberrant proteins and programming
a multicellular response by secreting proinﬂammatory
cytokines. Both processes are mediated by factors secreted
by T cells. However, endogenous or postvaccination immune
responses to tumor-associated antigens are less predictable
than the response to viral infections, and are generally less
effective at eliminating the offending cells. This response may
be due to lower-afﬁnity TCRs expressed on tumor-associated
antigen-speciﬁc T cells [17], inefﬁcient T cell priming of these
cells [21], and/or the presence of regulatory cytokines, factors,
or cells [22]. This diversity is reﬂected in the wide range of
clinical responses to experimental cancer vaccines [23]. Here,
we provide a possible explanation for this heterogeneity.
Using pMHC functional microarrays to analyze viable patient
T cells, we demonstrate a wide variation in the responses of
tumor-associated antigen-speciﬁc CD8þ T cells following
tumor peptide vaccination.
The mechanism that controls which speciﬁc factors are
secreted in response to T cell activation and the impact of
different functional proﬁles on the overall clearance of
tumor has not been established, but the remarkable hetero-
geneity of these responses highlights the importance and the
challenge of understanding these relationships. The differ-
ences in T cell behavior, as measured by multiple secreted
factors, may stem from differences between melanoma cells
from different patients, and the regulation of their T cell
responses to melanoma antigens. Melanoma cells themselves
may shape the behavior of tumor-associated antigen-speciﬁc
T cells via secreted factors, or cell-contact [24,25]. Recogniz-
ing differences in functional responses between patients and
between different antigen-speciﬁc T cells within a patient
should help guide the development of cancer vaccines by
providing causal relationships between treatment and clinical
outcome, thereby accelerating the testing of different vaccine
strategies.
Although this study is limited in scope, and does not allow
us to link speciﬁc secretion response proﬁles to clinical
outcomes, the results do suggest hypotheses that can be tested
in expanded studies. One such possibility is that active
secretion of both IFNc and TNFa in response to tumor-
associated antigen recognition may be necessary for effective
tumor clearance. As one of its many functions, TNFa can
mediate inﬂammation and promote T cell priming [26–28].
Similarly, IFNc can mediate increased MHC class I expression
Figure 6. Differences in Functional Profiles between Three Patients with Different Clinical Outcomes
gp100 209–2M spots co-spotted with anti-IFNc, anti-TNFa, anti-IL1b, and anti-IL-6 are shown for three separate patient samples. Patient 10735, who
remains free of disease at this writing, displays strong IFNc, TNFa, IL-1b, and IL-6 secretion. Patients 10710 and 10737 show strong IFNc secretion, but
weak to no TNFa, IL-1b, and IL-6 secretion; both patients experienced disease recurrence soon after these samples were drawn. Note the diffuse pattern
of IL-1b and IL-6 capture, which differs from the focal capture of IFNc and TNFa.
DOI: 10.1371/journal.pmed.0020265.g006
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toward a TH1 phenotype [29,30]. Without the involvement of
both factors, it is possible that a threshold level of
inﬂammation and effector activity is not reached. Another
possibility is that dual IFNc and TNFa secretion are
associated with other secreted factors of critical importance.
What is most important at this point, however, is that the data
described here show that cytotoxic cells with identical
speciﬁcity can have diverse functional response proﬁles. This
heterogeneity is likely to have profound consequences for the
functional speciﬁcity and clinical efﬁcacy of cellular immune
responses and may mirror the heterogeneity in clinical
outcomes seen in essentially all of the immunotherapy trials
performed to date [31,32]. With the methodology described
here, we should be in an excellent position to determine what
immune response proﬁle correlates best with a positive
clinical outcome.
The functional responses seen here do not seem to ﬁt into
easily categorized ‘‘good’’ or ‘‘bad’’ response proﬁles. Each
individual patient appears to have a unique signature of
functional responses. This is in contrast to preliminary
analysis of anti-inﬂuenza T cell responses following vacci-
nation (DSC and MMD, unpublished data). Furthermore, the
variation in the responses is both patient-speciﬁc and
independently antigen-speciﬁc. For example, individuals
who responded to gp100 209–2M with strong IFNc, but weak
TNFa secretion (e.g., patient 10710), could respond to
MART1 M26 with very strong IFNc and TNFa secretion, in
the same CD8þT cell sample analyzed on the same array. This
was also true of the variation in CD8þT cell responses to viral
antigens, in the absence of vaccination. As all patients
underwent a similar melanoma vaccination protocol, these
ﬁndings suggest that T cell populations with different antigen
speciﬁcities are differentially regulated in the same patient at
the same time, perhaps a major source of the variation in
functional responses. Interestingly, the strong IFNc and
TNFa response to gp100 209–2M/HLA-A2.1 and MART1
Figure 7. Antigen-Specific Profiles within Individual Patients
CD8þ lymphocytes were isolated from PBMCs from patients 10794, 10713, 10770, 10757, and 10742, and incubated on a pMHC functional cellular
microarray containing anti-IFNc co-spotted with several different peptide-MHC (HLA-A2) complexes. These included melanoma-associated antigens
gp100, MART-1, and tyrosinase, and viral antigens from cytomegalovirus, influenza virus, and Epstein-Barr virus (gp100 209–2M, MART1 M26, tyrosinase
370D, CMV pp65, influenza MP, and EBV BLF, respectively). The resulting IFNc responses varied by antigen-specific T cell population.
DOI: 10.1371/journal.pmed.0020265.g007
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still present in sample 10794 (same patient, after month 12).
The surprisingly multidimensional variation in the molec-
ular speciﬁcity of the cellular immune response to a peptide
vaccine raises the question of how and why these diverse
variations arise. One possibility is that T cells acquire speciﬁc
molecular programs based upon speciﬁc cues or signals
accompanying or following the encounter with cognate
antigen. Such signals could be mediated by secreted factors,
or require cell-cell contact and might originate from antigen-
presenting cells, CD4þ T cells, or a local complex inﬂamma-
tory response. We refer to such a possible system as the
‘‘acquisition model,’’ in which incremental gains in their
repertoire of functional responses (e.g., in the repertoire of
effectors secreted in response to antigen stimulation) would
change the CD8þ T cell’s ability to effect killing and
inﬂammation upon activation. An alternative possibility is
that all T cells emerge from priming with the same level of
functionality, capable of mediating a potent effector re-
sponse. Following priming, their function could change with
time, lack of stimulation, or the action of regulatory factors,
causing them to slowly lose their ability to respond effectively
to antigen recognition. We refer to this possibility as the
‘‘decay model’’ (Figure 8). Whether any stereotypical, ordered
progression for either acquisition or decay of the response
repertoire exists is unclear. However, our data do not support
a single stereotyped progression, as T cells from some
patients appear to respond with IFNc, but not TNFa, while
others respond with TNFa,b u tn o tI F N c. One ﬁnal
possibility, an ‘‘intrinsic model,’’ is that the differences in
functionality presented here are not evolving, but rather
reﬂect the selection of T cells with speciﬁc predetermined
molecular phenotypes. In this case, TCR afﬁnity and other
structural phenotypes might account for differences in
function following activation. Changes in functional proﬁles
in this model would reﬂect the emergence of new antigen-
speciﬁc clones.
Isolating Individual Events in Complex Immune System
Responses
The cellular arm of the adaptive immune response is based
on speciﬁc recognition of target antigens presented on the
surface of altered cells and subsequent triggering of a
complex scenario of responses, collectively termed effector
function. To investigate the cellular immune response to
antigen recognition, we have developed a high-throughput
multiparametric platform that simultaneously captures anti-
gen-speciﬁc T cells and facilitates parallel induction and
monitoring of distinct secreted factors from multiple T cell
speciﬁcities [33,34]. A similar approach that has been used for
the capture and analysis of antigen-speciﬁc T cell clones was
recently reported by Stone, et al. [35]. However, the technique
described here differs from that of Stone and colleagues in
several important aspects, including the selection of a surface
with lower cellular binding characteristics and greater
protein loading capacity. We have found these features to
be critical to the detection of rare populations of antigen-
speciﬁc T cells, and their secreted proteins, from clinical
specimens. Detection of antigen-speciﬁc T cell populations
on this platform compares favorably with approaches such as
pMHC tetramer staining followed by ﬂow cytometry. We have
noted a similar level of sensitivity for reproducible detection
of rare cell populations. Analysis of a single clinical sample on
the pMHC cellular microarray includes isolation, quantita-
tion, and activation of antigen-speciﬁc T cells, followed by
characterization of secreted proteins with single-cell reso-
lution. This type of analysis is impractical or impossible to
perform with more traditional approaches, such as pMHC
tetramer staining, ELISpot [36], and cytokine ﬂow cytometry
[37]. Unlike ELISpot assays or cytokine capture arrays, the
pMHC microarray immobilizes speciﬁc cells prior to func-
tional characterization. In addition, due to a higher concen-
tration of the coprinted detector probe antibodies, the
secreted factors are captured and subsequently detected in
close proximity to the secreting cells, with minimal dilution.
Figure 8. Two Models of T-Cell Function
Acquisition and decay models depict two possible mechanisms that account for variability in the factors secreted by activated CD8þT lymphocytes in
response to antigen recognition. Acquisition refers to independent, sequential increases in responsiveness to activation, triggered by both cellular and
secreted signals. Decay accounts for maximally functional T cells immediately upon completion of priming, after which signals, or time, lead to
diminished responsiveness to activation.
DOI: 10.1371/journal.pmed.0020265.g008
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may provide further clues to their physiologic roles and
mechanisms of action.
In some cases, the presence of unresponsive (i.e., non-
secreting) cells can also be determined based on a character-
istic signature of a nonﬂuorescent, cell-shaped region
embedded within a brighter region (see Figure 3). By
combining isolation with activation, antigen-speciﬁc T cells
can be studied under controlled environments, where the
inﬂuence of a speciﬁc factor or cell type can be ascertained.
Cospotting of additional membrane-bound ligands (e.g., B7–
1, ICAM), or even secreted factors (e.g., IFNc, TGFb, IL-2, IL-
15) may further help to elucidate the complex network of
interactions underlying T cell reactivity or lack thereof. The
spatial resolution of secreted factor detection on a pMHC
microarray is sufﬁciently high to distinguish between differ-
ent factors based on the characteristic signature of secretion.
For example, the IFNc signature appears as a focal secretion
characterized by an intense core, beyond which the signal
decays sharply (Figure 7). In contrast, the appearance of
captured TNFa is characterized by a clearly demarcated ring
that appears outside the edge of bound or previously bound
cells. These patterns suggest that IFNc secretion is polarized
toward the target cell, whereas TNFa is not detectable at the
contact interface; thus, it may be broadcasting a signal rather
than engaging in a dialog with the target cell (as also
indicated by work in murine T cells; M. Huse, personal
communication). The spatial resolution of detected cytokine
secretion also reveals marked differences in the quantity of
cytokine secreted by different T cells of the same antigen
speciﬁcity. However, it is unclear what mechanisms control
the quantity of cytokine secreted by a given responding T cell,
or the signiﬁcance of higher levels of secretion. One may
speculate that higher numbers of tumor-associated antigen-
speciﬁc T cells that secrete larger quantities of effector
cytokines favor a more effective antitumor response.
In humans, the T cell component of the immune system
comprises a tremendous number and diversity of T cells with
different antigen speciﬁcities. Proﬁling a large and diverse
range of T cell speciﬁcities on a single pMHC array platform
can allow more thorough interrogation and understanding of
ongoing responses from a single clinical sample. Here, we
tested a strategy for constructing very large pMHC arrays by
using a hybrid MHC (class I):Ig dimer construct that can be
easily loaded with an arbitrary HLA- restricted peptide. The
success of this approach suggests that a printable library of
diverse pMHC constructs can be prepared simply by loading
many different peptides in parallel.
The ability to generate functional proﬁles of cells present in
clinical samples is not limited to characterization of antigen-
speciﬁc T cell responses. This type of approach can be applied
using a wide range of cell adhesion and signaling molecules to
speciﬁcally capture cells in heterogeneous populations, and
proﬁle the molecules they secrete in response to speciﬁc
signals, with single-cell resolution. As is true with responding
CD8þ T cells, all cells use a diverse vocabulary of secreted
proteins to communicate with other cells and modify their
environment. Thus, the proﬁles that microarrays of this kind
can provide may give us insight into what different
populations of cells are capable of communicating and how
they can manipulate their environment. The patterns that
emerge from this type of systematic analysis could provide us
an understanding of the language of molecular communica-
tion among cells, and how groups of cells orchestrate their
behavior at the tissue level. This immediate improvement in
the resolution with which we can proﬁle the functional
characteristics of living human cells is likely to ﬁnd clinical
applications beyond tumor immunology.
Supporting Information
Figure S1. Expanded gp100 and MART-1 Speciﬁc T Cell Functional
Activity
The data used to generate Figure 5 are shown in this ﬁgure.
(A) Number of cells responding per spot to gp100 or MART1 with
secretion of IFNc or TNFa.
(B) Average intensity value gp100 spots and MART1 spots for each
individual secreted factor. Spot ﬂuorescence intensity was measured
from each spot and averaged over all replicates. Intensity values are
then expressed as a percentage of an arbitrary value speciﬁc for each
secreted factor.
Found at DOI: 10.1371/journal.pmed.0020265.sg001 (25 KB PDF).
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Patient Summary
Background Malignant melanoma is a common skin cancer that is
frequently fatal. One type of treatment being tested is vaccination with
peptides (very short lengths of proteins) that are found on the surface of
melanoma cells, in an attempt to produce an immune response to the
tumor, which will then clear the tumor. However, the success of this
treatment has been quite varied; in particular it has been very hard to
predict which patients will respond to treatments and which will not.
Why Was This Study Done? The authors wanted to understand why
some people respond to vaccination and others do not. One way of
measuring the response to vaccination is to look at the T cells (part of
the body’s immune response) that are specific to the melanoma proteins
and which are produced after vaccination, and to measure how active
they are in various ways.
What Did the Researchers Do and Find? The researchers developed a
way of catching individual T cells from the blood of patients onto a
surface, stimulating the cells, and then measuring how the cells
responded by measuring how much of various substances the cells
produced. They tested the responses of T cells from ten patients who
had been enrolled in a trial of vaccination against melanoma and found a
wide variation in how much of various substances the patients’ cells
secreted; in patients whose tumors did not get bigger, it seemed
necessary for the cells to secrete two particular compounds—interferon
gamma and tumor necrosis factor alpha.
What Do These Findings Mean? Unlike responses to vaccination for
infectious diseases, the response to tumor vaccination is highly variable
between patients. Studying the basis of these different responses may
guide the future development of more effective vaccines.
Where Can I Get More Information Online? Medline plus has links to
many pages of information on melanoma:
http://www.nlm.nih.gov/medlineplus/melanoma.html
Cancer Bacup in the UK also has information for patients:
http://www.cancerbacup.org.uk/Cancertype/Melanoma/Resourcessupport/
PatientInformationGuide
The National Cancer Institute has a page containing links to information
on melanoma:
http://www.cancer.gov/cancertopics/types/melanoma
The National Institutes of Health has a searchable index of ongoing
clinical trials for melanoma:
http://www.clinicaltrials.gov/ct/screen/SimpleSearch
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